Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study

• Franck Morschhauser,
• Kamal Bouabdallah,
• Stephan Stilgenbauer,
• Catherine Thieblemont,
• Sophie de Guibert,
• Florian Zettl,
• Lawrence M. Gelbert,
• P. Kellie Turner,
• Siva Rama Prasad Kambhampati,
• Li Li,
• Lily Q. Li,
• Sean Buchanan,
• Susana Barriga,
• Melissa M. Bear,
• Martin Wilhelm,
• Georg Hess

Affiliations

Franck Morschhauser

Hôpital Claude Huriez, Centre Hospitalier Regional Universitaire, Lille, France;

Kamal Bouabdallah

Hopital Haut-Levêque, Centre Hospitalier Regional Universitaire de Bordeaux, Pessac, France;

Stephan Stilgenbauer

Internal Medicine III, Ulm University, Ulm, Germany;

Catherine Thieblemont

Hemato-Oncology Department, Hôpital Saint-Louis and Diderot University, Paris, France;

Sophie de Guibert

Hôpital de Pontchaillou, Rennes, France;

Florian Zettl

Universitätsmedizin Göttingen, Göttingen, Germany;

Lawrence M. Gelbert

LMG PharmaTech, LLC., Indianapolis, Indiana, USA;

P. Kellie Turner

Eli Lilly and Company, Indianapolis, Indiana, USA;

Siva Rama Prasad Kambhampati

Eli Lilly and Company, Indianapolis, Indiana, USA;

Li Li

Eli Lilly and Company, Indianapolis, Indiana, USA;

Lily Q. Li

Eli Lilly and Company, Indianapolis, Indiana, USA;

Sean Buchanan

Eli Lilly and Company, Indianapolis, Indiana, USA;

Susana Barriga

Eli Lilly and Company, Indianapolis, Indiana, USA;

Melissa M. Bear

Eli Lilly and Company, Indianapolis, Indiana, USA;

Martin Wilhelm

Klinikum Nürnberg Nord, Nürnberg, Germany;

Georg Hess

Universitätsmedizin Mainz, Mainz, Germany